Citius Oncology, Inc. (CTOR) vs Hyperfine, Inc. (HYPR)
A side-by-side comparison of Citius Oncology, Inc. and Hyperfine, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CTOR
Citius Oncology, Inc.
$0.83HealthcareDelayed quote: Oct 6, 2026, 3:34 PM EDT
HYPR
Hyperfine, Inc.
$0.88HealthcareDelayed quote: Oct 6, 2026, 3:35 PM EDT
Total return — CTOR vs HYPR
growth of $100 · dividends reinvested · last 2yCTOR -92.4% (-72.4%/yr)HYPR -25.8% (-13.9%/yr)HYPR compounded faster over this window
Log scale — wide-divergence pair
CTOR HYPR
CTOR vs HYPR: by the numbers
- •CTOR is the larger company ($77M vs $74M market cap).
- •Both run net losses; HYPR's is the smaller (-210.75% vs -648.32% net margin).
Metrics side by side
Valuation
| Metric | CTOR | HYPR |
|---|---|---|
| Forward P/E | 8.31 | N/A |
| P/S ratio | 10.88 | 4.46 |
| P/B ratio | 1.91 | 2.01 |
Profitability
| Metric | CTOR | HYPR |
|---|---|---|
| Gross margin | 0.00% | 51.41% |
| Operating margin | 0.00% | -273.43% |
| Net margin | -648.32% | -210.75% |
| ROE | -114.06% | -94.81% |
| ROIC | -88.72% | -62.98% |
Growth (annualized)
| Metric | CTOR | HYPR |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 77.73% |
| Total return CAGR (5Y) | N/A | -38.34% |
Go deeper
Dig into the metrics
Citius Oncology ROEHyperfine ROECitius Oncology operating marginHyperfine operating marginCitius Oncology revenue growthHyperfine revenue growthCitius Oncology free cash flowHyperfine free cash flow
Citius Oncology & Hyperfine appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.